BTIG Research reaffirmed their buy rating on shares of Galapagos NV (NASDAQ:GLPG) in a report published on Monday morning. The firm currently has a $118.00 price objective on the biotechnology company’s stock.

A number of other brokerages have also weighed in on GLPG. Zacks Investment Research upgraded shares of Galapagos NV from a sell rating to a hold rating in a research report on Wednesday, October 11th. Stifel Nicolaus upped their target price on shares of Galapagos NV from $101.00 to $120.00 and gave the stock a buy rating in a research report on Friday, September 15th. Royal Bank Of Canada began coverage on shares of Galapagos NV in a research report on Thursday, September 14th. They set a sector perform rating and a $98.00 target price for the company. Morgan Stanley restated an overweight rating and set a $123.00 target price (up previously from $92.00) on shares of Galapagos NV in a research report on Friday, October 6th. Finally, BidaskClub upgraded shares of Galapagos NV from a sell rating to a hold rating in a research report on Thursday, August 17th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Galapagos NV presently has a consensus rating of Buy and an average price target of $111.00.

Galapagos NV (NASDAQ:GLPG) traded up $2.56 on Monday, hitting $93.39. 121,500 shares of the company’s stock were exchanged, compared to its average volume of 153,645. Galapagos NV has a fifty-two week low of $57.16 and a fifty-two week high of $104.12.

WARNING: This story was reported by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.watchlistnews.com/galapagos-nvs-glpg-buy-rating-reaffirmed-at-btig-research/1718074.html.

Hedge funds have recently added to or reduced their stakes in the business. Advisors Preferred LLC bought a new position in Galapagos NV during the third quarter valued at $105,000. Envestnet Asset Management Inc. lifted its position in Galapagos NV by 156.6% during the third quarter. Envestnet Asset Management Inc. now owns 1,742 shares of the biotechnology company’s stock valued at $177,000 after purchasing an additional 1,063 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Galapagos NV during the third quarter valued at $218,000. Acadian Asset Management LLC bought a new position in Galapagos NV during the second quarter valued at $166,000. Finally, New York State Common Retirement Fund bought a new position in Galapagos NV during the second quarter valued at $166,000. Institutional investors and hedge funds own 21.42% of the company’s stock.

About Galapagos NV

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Analyst Recommendations for Galapagos NV (NASDAQ:GLPG)

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with Analyst Ratings Network's FREE daily email newsletter.